Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Ragini R. Kudchadkar, John A. Thompson, Wim van Dijck, Michael Smylie, David Hogg, Kevin B. Kim, Maurice Lobo, Gregory A. Daniels, Anna C. Pavlick, Mario Sznol, David R. Spigel, Scott Ernst, Rene Gonzalez, Nikhil I. Khushalani, Christopher D. Lao, F. Stephen Hodi, Paul B. Chapman, William H. Sharfman, Michael B. Atkins, Jose Gerard Monzon
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
Autor:
Margarita Askelson, Igor Puzanov, Ragini R. Kudchadkar, Alain Algazi, Michael A. Postow, Omid Hamid, Nikhil I. Khushalani, Anna C. Pavlick, Karl D. Lewis, Hussein Abdul-Hassan Tawbi, John A. Glaspy, Christopher D. Lao, Kim Margolin, F. Stephen Hodi, Stergios J. Moschos, Ahmad A. Tarhini, Caroline Chung, David A. Reardon, Piyush Durani, Peter A. Forsyth, Reena Thomas, Sekwon Jang, M. S. Ernstoff, Corey Ritchings, Michael B. Atkins
Publikováno v:
The Lancet. Oncology, vol 22, iss 12
Lancet Oncol
Lancet Oncol
Summary Background Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM. Here, we provide final 3-year follow-up
Autor:
Melinda L. Yushak, Jim Zhong, David H. Lawson, David C. Qian, Brianna Brammer, Chrystal M. Paulos, Mohammad K. Khan, James Janopaul-Naylor, Troy Kleber, Jeffrey M. Switchenko, R. Donald Harvey, Karen M. Xu, Zachary S. Buchwald, Ragini R. Kudchadkar
Publikováno v:
The Lancet. Oncology. 22(12)
Summary Background The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infu
Autor:
Ragini R. Kudchadkar, Uwe M. Martens, Paul Nghiem, Robert L. Ferris, Julie E. Stein, Junchen Gu, Suzanne L. Topalian, Michi M. Shinohara, Adam Barrows, Christine H. Chung, Rima M. Kulikauskas, Jean Pierre Delord, Lara Dunn, Andrea Horvath, Janis M. Taube, Shailender Bhatia, Lot A. Devriese, William H. Sharfman, Bin Li, Céleste Lebbé, Tian Chen, Asim Amin, Elizabeth L. Engle, Christopher D. Lao
Publikováno v:
J Clin Oncol
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and
Autor:
Valerie Moberg, Xiuhua Zhao, Heather Cronin, Lori McCormick, Yian Ann Chen, Geoffrey T. Gibney, Bin Yu, Michael J. Schell, Ragini R. Kudchadkar, Jeffrey S. Weber, Allison Richards, PingYan Cheng, Jodie Kroeger, Alberto J Martinez
Publikováno v:
Cancer Immunology Research. 4:345-353
The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, in
Autor:
Anna C. Pavlick, Reena Thomas, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, F. Stephen Hodi, David A. Reardon, Omid Hamid, Karl D. Lewis, Joel Jiang, Alain Algazi, Michael B. Atkins, Sheena Demelo, Kim Margolin, Marc S. Ernstoff, Igor Puzanov, Christopher D. Lao, Ahmad A. Tarhini, Stergios J. Moschos, Ragini R. Kudchadkar, Nikhil I. Khushalani, Alexandre Avila, Michael A. Postow
Publikováno v:
The New England journal of medicine, vol 379, iss 8
BackgroundBrain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9842d318557841dc70e5ef68e3840d40
https://escholarship.org/uc/item/41x6h654
https://escholarship.org/uc/item/41x6h654
Autor:
Melissa S. Thebeau, Geoffrey T. Gibney, Ragini R. Kudchadkar, Jeffrey S. Weber, Cabell Eysmans, H. David Inzunza, Maria P. Czupryn, Leticia Tetteh, Kate Fisher, Ronald C. DeConti, Alberto J Martinez, Christine Horak, Michael J. Schell, Allison Richards, Ibrahim Younos, Bin Yu
Purpose: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. Exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed3763189ea926d47974a58f0920f2f
https://europepmc.org/articles/PMC4620684/
https://europepmc.org/articles/PMC4620684/